At this week’s Open Forums, you’ll hear information about Centegra’s preparation for the possible event that we encounter a patient suspected of having the Ebola virus. Centegra Health System is prepared. Key leaders are regularly meeting to ensure best practices are in place that align with the current recommendations from the Centers for Disease Control and Prevention (CDC).
Centegra takes this threat seriously. Our teams are working with the McHenry County Department of Health, Illinois Department of Health and other local agencies to ensure our response is well coordinated with our community partners. Please talk to your leader about your department’s role in our process.
Immediate isolation will be implemented for patients who have traveled to high-risk areas in Africa in the last 21 days and present with the following symptoms:
A fever of 100.5 or higher
All Associates and Physicians will wear Personal Protective Equipment (PPE) until Ebola is ruled out. Patients who call our facilities with these complaints will be triaged and directed through the Centegra Hospital-McHenry Emergency Department for instructions prior to arrival at the hospital.
Key contacts for more information:
CH-McHenry: Karen Van Buren, RN, Infection Preventionist 815-759-4574
CH-Woodstock: Cindy Schweder, RN, CIC, Infection Preventionist 815-334-3916
CPC and Centegra Immediate Care: Basia Scherbaum, RN, MSN 815-337-1985
Media Inquiries: Michelle Green, Senior PR Coordinator 847-341-0274
Enterovirus D68 (EV-D68) is one of many non-polio enteroviruses. Enterovirus D68 (EV-D68) infections are thought to occur less commonly than infections with other enteroviruses. EV-D68 was first identified in California in 1962. Compared with other enteroviruses, EV-D68 has been rarely reported in the United States for the last 40 years.
EV-D68 Infections Reported
Hospitals in Missouri and Illinois are seeing more children than usual with severe respiratory illness caused by enterovirus D68. Several other states are investigating clusters of children with severe respiratory illness, possibly due to enterovirus D68. CDC is watching this situation closely and helping the states with testing of specimens.
EV-D68 has been reported to cause mild to severe respiratory illness. However, the full spectrum of EV-D68 illness is not well-defined.
EV-D68 is not frequently identified, so it is less studied and the ways it spreads are not as well-understood as other enteroviruses. EV-D68 causes respiratory illness, and the virus can be found in respiratory secretions such as saliva, nasal mucus, or sputum. The virus likely spreads from person to person when an infected person coughs, sneezes, or touches contaminated surfaces.
There is no specific treatment for EV-D68 infections.
Many infections will be mild and self-limited, requiring only treatment of the symptoms.
Some people with severe respiratory illness caused by EV-D68 may need to be hospitalized and receive intensive supportive therapy.
No antiviral medications are currently available for treating of EV-D68 infections.
There are no vaccines for preventing EV-D68 infections.
You can help protect yourself from respiratory illnesses by following these steps:
Wash hands often with soap and water for 20 seconds, especially after changing diapers
Avoid touching eyes, nose and mouth with unwashed hands
Avoid kissing, hugging, and sharing cups or eating utensils with people who are sick
Disinfect frequently touched surfaces, such as toys and doorknobs, especially if someone is sick
Test to be ordered is “Enterovirus Molecular by PCR” fromARUP .Will be a Miscellaneous test in Paragon.
Specimen: Respiratory-bronch wash, BAL, Nasopharyngeal aspirate, sputum or tracheal aspirate.Volume is 1.5ml.
You may already be aware of the growing menace of global antimicrobial resistance. Among the measures to control the selection pressure it was felt that certain anti-infectives should be limited to the order of ID service.
Up until this time, only two anti-infectives had such limitation, polymyxin E (COLISTIN) and fidaxomicin (DIFICID). Several other agents will now be part of the restricted list. As you can see from the limitation list below, a number of these anti-infectives are currently non-formulary and in general are not commonly used and should therefore be reserved for specific cases.
We feel that this is an important and appropriate step in maintaining the current level of antimicrobial resistance that we are presently seeing at Centegra Hospitals. We are asking for your full support in this effort. If you have a patient that requires one or more of the drugs listed above, an ID consult will now be required.
Thank you for time and cooperation in this very important matter.
R. Damaraju, M.D. Co-Chair, Pharmacy & Therapeutics Committee
M. Hoffman, M.D. Co-Chair, Pharmacy & Therapeutics Committee